MELA Sciences, Inc. to Participate in the Fall Clinical Dermatology Conference

MELA Sciences, Inc. to Participate in the Fall Clinical Dermatology Conference

Leading Dermatologists to Present Clinical Findings in Four Poster
Presentations at the 32nd Annual Fall Clinical Dermatology Conference in Las
Vegas, Nevada

IRVINGTON, N.Y., Oct. 16, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind®, the first and only FDA approved optical diagnostic
device for melanoma detection used by dermatologists in their fight against
melanoma, today announced that the company will be participating in the 32^nd
Annual Fall Clinical Dermatology Conference taking place October 17 – 20, 2013
in Las Vegas, Nevada.

The Fall Clinical Dermatology Conference is a four-day sold-out medical
conference that is well attended by over 500 dermatologists, dermatology
residents, fellows, physician assistants and nurse practitioners. The
conference offers attendees cutting-edge information on the diagnosis and
treatment of various conditions related to medical, surgical and cosmetic

MELA Sciences will exhibit four poster presentations of clinical data that
demonstrate how MelaFind® has assisted dermatologists in making better biopsy
decisions and helped them identify early melanomas. The poster data was
derived from studies conducted in both clinical and practice settings and
reinforces the importance of MelaFind® as an optical imaging device for
dermatologists to aid them in the diagnosis of melanoma.

In addition, MELA Sciences will be hosting its first Clinical Advisory Meeting
among Key Opinion Leaders (KOLs) at the conference. Mark S. Nestor, MD, PhD,
Voluntary Associate Professor of the Department of Dermatology and Cutaneous
Surgery at the University Of Miami Leonard Miller School Of Medicine will be
moderating the company's Clinical Advisory Meeting during the conference along
with Darrell Rigel, MD, MS, Clinical Professor of Dermatology at New York
University, Langone Medical Center and MELA Sciences' Chief Medical Advisor to
the Board of Directors.

"Melanoma is an ever-growing problem for people of all ages, genders and skin
tones, especially those who are high risk, and prevention as well as early
detection are essential for survival," said Dr. Nestor. "I find MelaFind® to
be a useful tool in my practice especially when dealing with patients with
numerous moles with atypical appearance. MelaFind® can help me validate my
decision on whether or not to biopsy a marginal lesion, and may, in certain
cases allow me to feel comfortable following a lesion clinically instead of
performing a biopsy."

According to the Skin Cancer Foundation, melanoma is currently the deadliest
and fastest growing cancer in the U.S., with one American dying from melanoma
every hour. Skin cancer has reached epidemic proportions, even though the
cause (ultraviolet rays) and prevention (sun protection) is known. Melanoma is
almost 100% curable if caught early, but according to a Harris Interactive
Study commissioned by MELA Sciences only 24 percent of American adults have
had a skin check by a dermatologist, which can lead to missed cases as well as
potentially advanced and fatal stages.

MelaFind® is the first and only FDA-approved optical imaging device for
melanoma detection used by dermatologists and was recognized by the Cleveland
Clinic as a Top 10 Medical Innovation for 2013. MelaFind® was featured in the
Wall Street Journal, and recently received national attention on "The Rachael
Ray Show". Consumers can learn more about the device or locate a MelaFind®
dermatologist in their area by visiting

About MELA Sciences, Inc.

MELA Sciences, Inc. is a medical device company focused on the
commercialization of its flagship product, MelaFind® and its further design
and development. MelaFind® is a non-invasive tool that provides additional
information to dermatologists during melanoma skin examinations. The device
uses light from visible to near-infrared wavelengths to evaluate skin lesions
up to 2.5 mm beneath the skin. The device supplies information on a lesion's
level of morphologic disorganization to provide additional objective
information that may be used by dermatologists in the biopsy decision-making
process. MelaFind® has been approved by the U.S. Food and Drug Administration
for use in the U.S. In addition, MelaFind® has received CE Mark approval and
is approved for use in the European Union.

For more information on MELA Sciences, Inc., visit

Safe Harbor:

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at and

CONTACT: Investors
         Lynn Pieper
         Westwicke Partners
         Erica Sperling
         Rpr Marketing Communications
Press spacebar to pause and continue. Press esc to stop.